The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CA IX-expressing tumors.
 
Darren R. Feldman
Consulting or Advisory Role - BioNTech; Cigna
Research Funding - Astellas Pharma; Decibel Therapeutics (Inst); Telix Pharmaceuticals
Other Relationship - UpToDate
 
Ben Tran
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Janssen-Cilag; Pfizer; Sanofi; Tolmar
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; IQvia; Janssen-Cilag; MSD Oncology; Novartis; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche Molecular Diagnostics; Sanofi; Tolmar
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb; Genentech (Inst); Ipsen; Janssen-Cilag (Inst); Merck Sharp & Dohme; Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma
 
Louise Emmett
Consulting or Advisory Role - Clarity Pharmaceuticals; Noxopharm
Speakers' Bureau - Astellas Pharma (Inst); Janssen Oncology; Janssen Oncology; mundipharma
Research Funding - Novartis (Inst); Novartis (Inst); Noxopharm (Inst); Noxopharm (Inst)
 
Michael S Hofman
Consulting or Advisory Role - Janssen; POINT Biopharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Janssen; Mundipharma
Research Funding - Bayer (Inst); Isotopia (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Genzyme; Ipsen; Janssen; Novartis
 
Pierre Olivier
No Relationships to Disclose
 
Hakim Mahammedi
Honoraria - AAA/Endocyte/Novartis; Astellas Pharma; AstraZeneca; Bayer Schering Pharma; BMS; Janssen-Cilag; MSD Oncology; Novartis; Pfizer
Consulting or Advisory Role - Bayer; BMS
Travel, Accommodations, Expenses - Janssen-Cilag; Pfizer
 
Ivana Galetic
Employment - Debiopharm Group
Leadership - Advanced Accelerator Applications; Debiopharm Group
Stock and Other Ownership Interests - Alcon; Novartis
 
Anna Pokorska-Bocci
Employment - Debiopharm Group
 
Florilene Bouisset
Employment - Debiopharm Group
 
Kathrin Gollmer
Employment - Debiopharm Group
 
Mariya Pavlyuk
Consulting or Advisory Role - Debiopharm Group
Travel, Accommodations, Expenses - Debiopharm Group
 
Libuse Tauchmanova
Employment - Debiopharm Group; Telix Pharmaceuticals
Stock and Other Ownership Interests - Novartis
 
Ken Herrmann
Leadership - Pharma15; SOFIE; Theragnostics
Stock and Other Ownership Interests - Aktis Oncology; Pharma15; SOFIE; Theragnostics
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Bain Capital; Bayer; BTG; GE Healthcare; IPSEN; ITG (Inst); Novartis; ROTOP Pharmaka (Inst); Siemens Healthineers